In 21 participants evaluable for toxicity, frequent (≥ 10%) non‐dose‐limiting Grade ≥ 3 adverse events at least possibly related to protocol therapy, included anemia, decreased WBC, decreased ANC, decreased lymphocyte count, increased ALT, and hypophosphatemia (Table S1). This evidence concerns the gene GPT and anemia (phenotype).